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Currently, patients awaiting deceased-donor liver
transplantation are prioritized by medical urgency.
Specifically, wait-listed chronic liver failure patients
are sequenced in decreasing order of Model for End-
stage Liver Disease (MELD) score. To maximize life-
time gained through liver transplantation, posttrans-
plant survival should be considered in prioritizing liver
waiting list candidates. We evaluate a survival benefit
based system for allocating deceased-donor livers to
chronic liver failure patients. Under the proposed sys-
tem, at the time of offer, the transplant survival benefit
score would be computed for each patient active on
the waiting list. The proposed score is based on the
difference in 5-year mean lifetime (with vs. without a
liver transplant) and accounts for patient and donor
characteristics. The rank correlation between benefit
score and MELD score is 0.67. There is great overlap
in the distribution of benefit scores across MELD cat-
egories, since waiting list mortality is significantly af-
fected by several factors. Simulation results indicate
that over 2000 life-years would be saved per year if
benefit-based allocation was implemented. The short-
age of donor livers increases the need to maximize
the life-saving capacity of procured livers. Allocation of
deceased-donor livers to chronic liver failure patients
would be improved by prioritizing patients by trans-
plant survival benefit.
Key words: Albumin, bilirubin, creatinine, Model for
End-stage Liver Disease (MELD), organ allocation,
Organ Procurement and Transplantation Network
(OPTN), Scientific Registry of Transplant Recipients
(SRTR), waiting list
Introduction
In all areas of medicine, it is essential to determine whether
or not a patient will benefit from a given treatment. In
the case of organ failure, such questions are perhaps
even more important since the preferred treatment (organ
transplantation) is not available for all patients. In certain
cases, even if there were a sufficient number of donor
organs, certain types of patients would be better off not
receiving a transplant (1,2) since their waiting list mortality
is not sufficiently high to offset the high post and peri-
operative mortality, which is now well-established in the
literature (3).
There are at least three possible bases for organ allocation:
medical urgency; utility and transplant benefit. Typically,
the prioritization of patients active on the waiting list on a
particular date depends strongly on the allocation scheme.
Under a medical urgency-based allocation system, patients
with worse waiting list outcomes are given higher prior-
ity for transplantation. Conversely, a utility-based system
would assign priority in accordance with expected post-
transplant outcomes. An allocation scheme based on trans-
plant benefit considers both waiting list and posttransplant
outcomes. For example, a patient’s priority for transplanta-
tion could be based on the contrast between two settings:
(1) the patient receives the allocated organ and (2) the pa-
tient receives no organ.
Each of the allocation schemes mentioned in the preced-
ing paragraph (urgency, utility, benefit) has advantages and
disadvantages. For concreteness, suppose that the only
outcome considered is mortality. An urgency-based sys-
tem succeeds in assigning donor organs to patients who
are most likely to die on the waiting list. However, this ap-
proach may be at the expense of utility since patients at
the greatest risk of waiting list death may also be the pa-
tients with the highest posttransplant mortality. One can
envision an extreme case where medical urgency-based
allocation does not result in any fewer deaths, but merely
shifts mortality from the pre- to posttransplant side. Con-
versely, a utility-based allocation system would ensure that
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transplanted organs are received by patients with lowest
posttransplant mortality. However, patients with the best
posttransplant outcomes may also have the best waiting
list outcomes. In an extreme case, an ordering based on
utility could also result in transplantation having no effect
on the mortality experience of the patient population, since
the low death rate faced by the low-risk patients is merely
traded for a low posttransplant death rate. This is different
from the extreme scenario we described for an urgency-
based system, where a high death rate on the waiting
list is traded for a high posttransplant death rate. In both
cases, however, the lifetime experienced by the patient
population is equal to that in the absence of access to
transplantation.
A survival benefit based allocation system seeks to min-
imize mortality to the patient population as a whole by
prioritizing patients based on their lifetime gained due to
transplantation. To see that maximizing survival benefit re-
sults in minimizing patient population mortality, consider
the fact that every patient is guaranteed at least their wait-
ing list lifetime. In the absence of transplantation, all pa-
tients would experience their waiting list lifetime and that
alone. Suppose that one donor organ is available for trans-
plantation and to be allocated. If that one organ is trans-
planted, the recipient receives his/her waiting list lifetime,
plus any gain in lifetime attributable to the transplant (the
transplant survival benefit). Therefore, allocating the one
available organ to the patient with the largest difference
in posttransplant and waiting list lifetime (i.e. the greatest
transplant survival benefit) will minimize mortality for the
patient population as a whole.
In Table 1, we illustrate the last concept from the pre-
ceding paragraph that allocating an available organ to the
patient with the greatest transplant benefit maximizes the
total life-years lived by the patient population. In this sim-
plified setting, there are three patients on the waiting list
at the time a donor organ is to be allocated. The columns in
Table 1 are (left to right) ID: patient identification number;
WL: predicted waiting list lifetime (i.e. lifetime if no trans-
plant is received); LT: predicted posttransplant lifetime (with
the organ to be allocated); B: transplant benefit, computed
as LT–WL; years lived, summed across all three patients,
with row x representing the setting wherein the organ is
allocated to patient with ID = x. If an urgency-based alloca-
tion system were in place, the organ would be allocated to
patient 2, who has the lowest expected waiting list lifetime.
Under a utility-based system, patient 1 would receive the
transplant since that patient is predicted to live the longest
with the organ. Under a benefit-based allocation system,
the organ would go to patient 3, who is predicted to have
neither the greatest posttransplant lifetime nor the lowest
waiting list lifetime but the greatest difference between
the two.
Continuing with our examination of Table 1, if indeed the
organ was allocated to patient 3, as it would be under a





ID B = (patient population) if
no. WL LTx LTx – WL assigned to candidate (ID no.)
1 7 10 3 17 = 10 + 2 + 5 = 3 + (7 + 2 + 5)
2 2 3 1 15 = 7 + 3 + 5 = 1 + (7 + 2 + 5)
3 5 9 4 18 = 7 + 2 + 9 = 4 + (7 + 2 + 5)
B = transplant benefit.
ID = patient identification number.
LTx = predicted post transplant lifetime.
WL = predicted waiting list lifetime.
survival benefit based allocation scheme, the lifetime lived
by the patient population as a whole would equal 18 years;
that is, 7 (patient 1, who remains on the waiting list) + 2
(patient 2, also left on the waiting list) + 9 (posttransplant
lifetime of patient 3) years. The population lifetime calcula-
tion can be done in a more transparent way as follows. In
terms of total lifetime, the worst that could happen is that
the organ is not allocated, in which case all three patients
remain on the waiting list. If the organ is allocated, the ad-
ditional lifetime (i.e. transplant benefit) will be experienced
by only the patient who receives the organ. Consider the
left-most calculation in row 3 of Table 1. If the organ is allo-
cated to patient 3, each patient is predicted to receive their
waiting list lifetime (7+ 2 + 5), and patient 3 is predicted
to receive their WL lifetime, plus the gain in lifetime due
to the transplant (4 years). Since, irrespective of to whom
the organ is allocated, each patient is predicted to receive
at least their waiting list lifetime, the maximum gain to the
patient population as a whole will occur if the patient with
the greatest benefit score receives the organ. Although
this example considers a very simple scenario, the main
ideas extend to more general settings.
Currently in the United States, deceased-donor livers are
allocated based primarily on medical urgency. Specifically,
acute liver failure patients (Status 1) are given top prior-
ity, while chronic end-stage liver disease patients are se-
quenced on the liver waiting list in decreasing order of
Model for End-stage Liver Disease (MELD) score (4–6). In
February 2002, the MELD system replaced the Status sys-
tem, which was based largely on the Child–Turcotte–Pugh
(CTP) score (7,8). Both the CTP and MELD systems are
based on medical urgency, since both utilize scores that
are intended primarily to reflect waiting list mortality. Al-
though not a transplant benefit based system (since post-
transplant outcomes are not considered), the CTP system
represented a great improvement over a system that did
not prioritize waiting list patients based on their character-
istics, for example, a system that ranks patients based on
waiting time. Several articles have compared the MELD
and CTP scores (9). Almost always, in instances where
the analysis found a significant difference between the
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two scores, MELD was found to more accurately predict
waiting list mortality (6). In many cases, however, MELD
and CTP scores were not significantly different as predic-
tors of waiting list mortality, due perhaps to inadequate
sample size. However, even if one believed the two scores
to be equally predictive of waiting list mortality, a sys-
tem based on MELD would better achieve the objective of
urgency-based allocation, since MELD has a finer gradation
of risk. Ties are essentially broken by waiting time under
either system, meaning that ranks based on the CTP score,
which produces more ties, would be more influenced by
waiting time. Despite its initial appeal as being equitable,
allocation by waiting time identifies patients who have al-
ready survived the longest on the waiting list and, in some
cases, selects patients for transplantation who need the
organ the least. In sum, one would expect that CTP-based
allocation is much closer to optimal than allocation by wait-
ing time, and that allocation by MELD constitutes a further
considerable improvement.
Although the MELD system has proven effective, it was
not designed to reflect posttransplant survival. The per-
sistent shortage of donor livers increases the pressure to
make the best possible use of those available, which im-
plies that in addition to urgency, utility be considered. As
such, the Organ Procurement and Transplantation Network
(OPTN) Liver and Intestine Committee is currently evaluat-
ing a transplant survival benefit based system of allocating
deceased-donor livers to chronic end-stage liver disease
patients. We must emphasize that the development of a
benefit-based allocation system is a work in progress. This
article represents the state of the proposal at the time
of its writing. In terms of evaluating and testing the pro-
posed system, much work remains before implementa-
tion can occur. Several important decisions have yet to be
made, and some, which have been made, are subject to
modification.
The remainder of this article is organized as follows. In
Measuring Transplant Survival Benefit, we discuss the
quantification of transplant survival benefit and describe
the currently proposed benefit score. The posttransplant
and waiting list survival models are discussed in Posttrans-
plant Survival Model and Waiting List Survival Model, re-
spectively. We evaluate the proposed transplant benefit
score in Analysis Of Proposed Liver Transplant Survival
Benefit Score, including comparisons to the MELD and var-
ious other scores. We evaluate the implications of benefit-
based allocation through microsimulation in Evaluation of
Benefit-Based Allocation Via Simulation. A Discussion con-
cludes the article.
Measuring Transplant Survival Benefit
We quantify the liver transplant survival benefit for a given
candidate as that candidate’s 5-year mean lifetime with a
transplant (specifically, with the organ to be allocated) mi-
nus his/her 5-year mean lifetime without a transplant. Thus,
each time an organ is to be allocated, the transplant ben-
efit score would be computed for each chronic liver failure
patient active on the waiting list. In this sense, the scores
are patient- and organ-specific. After computing each of
their benefit scores, all active patients would then be se-
quenced in decreasing order of benefit score. In principle,
the calculation of the benefit score is straightforward. For
any donor–patient combination, a predicted posttransplant
survival curve is available (described in Posttransplant Sur-
vival Model), as is a predicted waiting list survival curve
(Waiting List Survival Model). In each case, the predicted
future lifetime is the area under the survival curve out to
5 years, while the benefit score is then the difference be-
tween those two predictions. For example, if the area un-
der the first 5 years of a patient’s posttransplant survival
curve equals 3.5, then that patient is expected to live 3.5 of
the next 5 years with the transplant. If the patient’s benefit
score equals 1.5, then it is predicted that out of the next
5 years, the patient will live an extra 1.5 years with the
transplant compared with the scenario where the patient
receives no transplant. That is, the area between the post-
transplant and waiting list survival curves (both followed
out to the 5-year point) equals 1.5 years. The calculation
is truncated at 5 years for two reasons. First, the available
data provided 5 years worth of pertinent follow-up. Second,
lifetime distributions are often skewed far to the right (i.e.
the histogram has a long right tail), and the unrestricted
mean would be too heavily influenced by this tail.
In Posttransplant Survival Model and Waiting List Survival
Model we describe the posttransplant and waiting list sur-
vival models, respectively. Before doing so, it is useful
to briefly compare our proposed approach for estimating
transplant benefit with others in the literature. Several au-
thors have quantified the survival benefit of liver transplan-
tation (1,10) and kidney transplantation (1,2,11,12). Each
of these works used a single Cox regression model with
‘transplant’ coded as a binary indicator. That is, one model
applies to both the waiting list and the posttransplant
deaths, with the regression parameter corresponding to
the transplant 0/1 indicator used to quantify the covariate-
adjusted survival benefit of transplantation. As mentioned
previously, we use separate models for waiting list and
posttransplant survival, similar in spirit to the Lung Alloca-
tion Score (13) and the proposed Life Years From Trans-
plant (LYFT) score to be used in deceased-donor kidney
allocation (14).
Having discussed our proposed transplant survival benefit
metric, we describe in the next two sections the post-
transplant and waiting list models used in its calculation.
Each step in the process of building and evaluating the sur-
vival models was carried out in consultation with the OPTN
Liver and Intestine Committee, as well as SRTR clinicians,
surgeons and biostatisticians.
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Posttransplant Survival Model
The transplant study population included patients who re-
ceived a deceased-donor liver transplant between Septem-
ber 1, 2001 and December 31, 2007. Follow-up began
(time 0) at the date of transplant and ended at the earli-
est of death, retransplant or loss to follow-up. The death
event was considered to be the earliest of death and liver
retransplant. While there is no question any lifetime (post-
transplant or otherwise) ends upon death, whether post-
transplant lifetime ends at retransplant requires more care-
ful thought. Basically, one organ is allocated at a time,
and of interest is a potential recipient’s predicted life-
time with that particular organ. Therefore, in the post-
transplant modeling, if a patient was retransplanted, their
lifetime with the original organ was considered to have
ended.
Posttransplant survival was modeled using Cox regres-
sion (15). Although several regression models are available
for survival analysis, the Cox proportional hazards model
dominates the biomedical literature. The original article in
which the Cox model was proposed (15) is among the
most cited article in science. Covariate selection was a
nonautomated form of backward elimination. Specifically,
we started the model-building process by fitting a model
that contained every covariate suspected of affecting pa-
tient or graft survival. This set of covariates consisted of all
covariates included in the Program-Specific Report (PSR)
models (used to compare center-specific mortality with
the covariate-adjusted national average) and/or included
in previous SRTR analyses of liver transplant mortality or
survival benefit, as well as various additional covariates
suggested by members of the SRTR or the OPTN Liver
Committee.
The final model consisted of recipient factors: creatinine,
albumin, sodium, age, diagnosis, diabetes, dialysis, hospi-
talization status, previous liver transplant, mechanical sup-
port, portal vein thrombosis, previous abdominal surgery,
hepatitis C; donor factors: age, cause of death, dona-
tion after cardiac death and transplant factors (i.e. donor–
recipient factors): cold ischemia time, and whether or not
the transplant represented a regional or national share.
In Table 2, we list the recipient factors included in the
posttransplant mortality model. There is a baseline death
rate that applies to all patients, and the hazard ratios (HR)
listed in Table 2 are the multipliers of this baseline death
rate. For example, a patient with a previous liver transplant
(HR = 1.60) has a death rate 60% greater than a patient
who would be receiving their first liver transplant. Donor
factors included in the benefit score calculation are listed in
Table 3. Note that the ‘Donor age ≥60 years and recipient
HCV’ entry in Table 3 (fifth row) represents an interaction
term. Specifically, from the fourth row, having a donor age
≥60 years confers a 44% increase in risk since the hazard
ratio is estimated at HR = 1.44. If, in addition, the recipi-
ent is HCV+, then donor age ≥60 years results in a greater
Table 2: Recipient characteristics used in posttransplant mean
lifetime prediction
Covariate Hazard ratio p
Age − 18 years 1.01 0.47
(Age − 18 years) × I (age > 18 years) 0.99 0.33
(Age − 55 years) × I (age > 55 years) 1.03 <0.0001
Diagnosis = cholestatic 0.80 0.0002
Diagnosis = noncholestatic 0.85 0.0002
Diagnosis = acute hepatic necrosis 0.86 0.10
Diagnosis = malignancy 1.20 0.17
Diagnosis = biliary atresia 0.69 0.007
Diagnosis = HCV 1.25 <0.0001
Hepatocellular carcinoma 1.15 <0.0001
Diabetes 1.16 <0.0001
Dialysis (at last WL status update) 1.17 0.005
Hospitalized: ICU 1.34 <0.0001
Hospitalized: not ICU 1.16 <0.0001
Previous liver transplant 1.60 <0.0001
Mechanical support 1.54 <0.0001
Previous abdominal surgery 1.13 <0.0001
Portal vein thrombosis 1.32 <0.0001
Creatinine: 4th quartile 1.19 <0.0001
Albumin: 1st quartile 1.15 <0.0001
Growth failure 1.34 0.04
I(A) = applies to patients with characteristic A.
HCV = hepatitis C.
ICU = intensive care unit.
WL = waiting list.
than twofold increase in posttransplant mortality risk, since
the hazard ratio is given by HR = 1.44 × 1.41 = 2.03.
Outputs from the final posttransplant Cox model include
the hazard ratios corresponding to each covariate and the
baseline survival. The latter can be interpreted as the
survival curve for a recipient–donor combination, whose
characteristics are described by the reference levels of
each covariate. Combining the baseline survival (which ap-
plies to all patients and donors) and the HRs, a predicted
survival curve can be constructed for any patient–donor
Table 3: Donor characteristics used in posttransplant mean life-
time prediction
Covariate Hazard ratio p
Donor age: < 18 years 0.89 0.03
Donor age: 40–49 years 1.16 <0.0001
Donor age: 50–59 years 1.35 <0.0001
Donor age: ≥ 60 years 1.44 <0.0001
Donor age: ≥ 60 years 1.41 <0.0001
and recipient HCV
Donor race: African American 1.14 0.0002
Donor race: Hispanic 1.15 0.0002
Cause of death: anoxia 1.07 0.07
Cause of death: cerebrovascular 1.12 0.0002
accident
Donation after cardiac death 1.78 <0.0001
HCV = hepatitis C.
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combination. Five-year posttransplant life expectancy can
then be computed as the area under the survival curve,
out to 5 years.
To evaluate the fit and predictive ability of the posttrans-
plant survival model, we computed the index of concor-
dance (or C statistic) based on all patients transplanted
in the calendar year 2005. The C statistic is an estimator
for the percentage of times that the model correctly pre-
dicts which of two patients will die first. To compute the
C statistic, the denominator equals the number of pairs
of patients where the ordering of the death times is ob-
served. The numerator is the subset of the denominator
where the ordering of the death times observed is concor-
dant with that predicted by the model. If C = 1, then the
model is estimated to perfectly predict the first of any two
patients to die. If C = 0.5, the model predicts the first of
two patients to die as well as would the toss of a coin. For
the posttransplant model, C = 0.63, indicating satisfactory
albeit not exceptional predictive ability. To cross-validate
the posttransplant survival model, we randomly split the
data set, fitted a Cox model to one half of the patients and
computed the C statistic on the other half. We repeated
this exercise 10 times, and the average C statistic equaled
0.63, indicating that our internal validation did not appear to
overstate the ability of the model to predict posttransplant
survival for future patients.
Waiting List Survival Model
To model waiting list survival, the study population con-
sisted of 10 cross-sections of patients, the cross-section
dates being May 1 and November 1 of each of calendar
years 2002–2006. To be included in a particular cross-
section (e.g. 11/01/2003), a patient would have to be alive
and active on the waiting list as of 11/01/2003. Status 1
patients were excluded. We formed the study population
using cross-sections since, when used for allocation, the
model will be applied to cross-sections of patients (those
active on the waiting list on a given date), as opposed to
cohorts of patients. The survival time was defined as time
since cross-section, with time previously survived on the
waiting list included as a covariate in the model. After being
included in a cross-section, patients were censored at the
earliest of loss to follow-up or receipt of a liver transplant. To
clarify, being active on the waiting list was a requirement
to be included in a cross-section. However, subsequent
deactivation would not be treated as a censoring event.
As mentioned in the preceding paragraph, patients were
censored upon receipt of a liver transplant. Under the
MELD system, patients at the highest risk of waiting list
death also generally have the highest transplant rate. The
potential bias was corrected through inverse probability of
censoring weighting (16,17), a well established method
to overcome dependent censoring. Specifically, a time-
dependent weight is applied to each cross-section patient,
with the weight being equal to the inverse of the probability
that the patient remains untransplanted. Basically, patients
with a higher (lower) probability of receiving a liver trans-
plant are assigned a higher (lower) weight to balance out
the fact that relatively less (more) follow-up on such pa-
tients is actually observed. To compute the weights, we
need a time to transplant model, which contains all covari-
ates in the waiting list survival model, plus time-dependent
MELD and organ procurement organization.
The statistical methodology and other technical issues sur-
rounding our approach to modeling waiting list mortality
will be described in a separate report. The underlying ideas
are given in some detail in the literature (12,18). Several
SRTR (2,10) and other analyses (19) have been carried out
using closely related methods. Related methodologic ma-
terial can be found in Liang and Zeger (20), Wei et al. (21)
and Zheng and Heagerty (22).
Cox regression was used to model waiting list survival.
Covariate selection proceeded in a manner similar to that
employed for the posttransplant survival model (Posttrans-
plant Survival Model). Patients were classified based on
their most recent measurement as of the cross-section
date for lab measures such as the MELD components, al-
bumin and serum sodium. This is appropriate since, when
the score is computed in practice, only current and pre-
vious lab measurements will be known. Covariates were
also defined for the slopes of each patient’s prior bilirubin,
creatinine, international normalized ratio (INR) and albumin
values. Patient characteristics in the final waiting list model
included creatinine, bilirubin, INR, albumin, sodium, age,
body mass index, previous time on waiting list, diagnosis,
diabetes, dialysis, medical condition at listing and prior his-
tory of malignancy. Table 4 lists the patient characteristics
included in the waiting list lifetime prediction.
To evaluate its discriminatory ability, we computed the C
statistic for the waiting list survival model. Based on the
cross-section of patients active on the waiting list on May
1, 2004, C = 0.74, indicating fairly good predictive abil-
ity. The cross-validation of the waiting list survival model
proceeded analogously to that described earlier for the
posttransplant model; that is, randomly splitting the data
in half, then fitting the model to one half and computing
the C statistic on the other half. Averaging over 10 random
splits, the C statistic equaled 0.74.
Analysis of Proposed Liver Transplant
Survival Benefit Score
Our objective in this section is to examine the proposed
liver transplant benefit score and to compare it with the
MELD score. We used the 10 cross-sections of patients
already selected as the study population for the waiting
list survival model. Within each cross-section, for each
selected patient, we used the most recent lab MELD
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Table 4: Characteristics used in waiting list mean future lifetime
prediction
Covariate Hazard ratio p
Previous time on WL: 6 months–1year 0.94 0.0007
Previous time on WL: 1–2 years 0.87 <0.0001
Previous time on WL: 2–3 years 0.83 <0.0001
Previous time on WL: 3–4 years 0.78 0.0002
Previous time on WL: 4–5 years 0.66 0.0005
Previous time on WL: >5 years 0.47 0.03
BMI: 30–35 0.87 0.005





Sodium: ≤131 1.89 <0.0001
Sodium: 132–137 1.22 <0.0001
HCC 1.51 <0.0001
Diagnosis = HCV 1.15 0.0006
Diabetes 1.26 <0.0001
Prior malignancy 1.24 0.036
Growth failure 2.11 0.016
Age −18 years 1.031 0.08
(Age −70 years) × I(age > 70 years) 1.045 0.18
Slope: creatinine 1.095 0.09
Slope: bilirubin 1.032 0.26
Slope: albumin 1.042 0.07
BMI = body mass index.
HCC = hepatocellular carcinoma.
HCV = hepatitis C.
I(A) = applies to patients with characteristic A.
INR = international normalized ratio.
WL = waiting list.
1coded as log(1 + x).
score and computed the proposed transplant survival ben-
efit based on a typical liver donor; specifically, a donor
with characteristics at the reference level for all categorical
donor factors and approximately equal to the median of all
continuous donor factors.
In Figure 1, we plot mean 5-year predicted future waiting



































Figure 1: Mean 5-year future life-
time by MELD.
MELD score. It is clear that predicted waiting list lifetime
strongly decreases as MELD increases, which would be
expected since MELD is a very strong predictor of wait-
ing list mortality. Mean predicted 5-year future waiting list
lifetime equals approximately 4.5 years for patients with a
MELD score of 6, meaning that on average, a patient with
a MELD of 6 would be expected to live 4.5 of the next
5 years. In contrast, mean 5-year waiting list lifetime is
only 0.5 years for patients on the waiting list with a MELD
score of 40.
Also plotted in Figure 1 is mean 5-year posttransplant life-
time. Posttransplant life expectancy decreases as MELD
increases, although the strength of the decrease is much
less than for waiting list lifetime. Patients with a MELD
score of 6 are expected to live an average of 4.1 years
out of the next 5 years if they receive a liver transplant;
this is an average of 0.4 years less than if they remain
on the waiting list. Patients with such a low MELD score
do not, on average, benefit from liver transplantation be-
cause their waiting list mortality is too low to offset the
high post- and perioperative mortality risk associated with
liver transplantation.
Average 5-year transplant benefit is the distance between
the two lines in Figure 1. We plot average survival ben-
efit by integer MELD score in Figure 2. Average survival
benefit increases steadily as MELD increases; consistent
with the fact that as MELD increases, mean waiting list
lifetime decreases at a much greater rate than mean post-
transplant lifetime. On average, patients with MELD less
than 10 have negative benefit scores, indicating reduced
lifetime posttransplant, based on a 5-year time horizon. It
is estimated that patients with a MELD score of 40 gain
an average of three (out of a possible five) future years if
they receive a liver transplant.
Of note, Figures 1 and 2 are based on averages. Overlook-
ing this fact could lead one to believe that allocating livers
by survival benefit would essentially amount to allocating
by MELD, since the trends appear to be in the same di-
rection. However, it is possible that patient X could have a



























Figure 2: Mean 5-year transplant
benefit by MELD.
much greater MELD score than patient Y, yet have a lower
benefit score. True, the MELD score consists of three very
strong predictors of waiting list mortality. However, recent
evidence suggests that the MELD components are not
weighted optimally in the MELD formula (23). Moreover,
one of the MELD components, creatinine, is also a very
strong predictor of posttransplant mortality (24). Since cre-
atinine predicts both waiting list and posttransplant mor-
tality, its effect on the benefit score is of less magnitude
than one might expect. Moreover, as identified in Measur-
ing Transplant Survival Benefit and Posttransplant Survival
Model, several factors in addition to the MELD compo-
nents predict waiting list and/or posttransplant mortality.
As a result, there is considerable variability in the distri-
bution of the benefit scores at any MELD score, as ev-
idenced by the box and whisker plots in Figure 3. Note
that the boxes in Figure 3 contain the middle 50% of the
data (spanning the 25th and 75th percentiles), while the
whiskers contain the middle 90%. The pattern in the av-
erages observed in Figure 2 are consistent with the trend
repeated in the boxes in Figure 3. However, what is much
more prominent is the degree of overlap; not just among



































Figure 3: Transplant benefit by
MELD box plots.
MELD scores three and four categories apart. Although,
MELD 6–8 patients do not, on average, benefit from liver
transplantation (Figure 3), approximately 20% of such pa-
tients do have positive benefit scores (Figure 3). Similarly,
there are patients with MELD ≥21 with negative bene-
fit scores (Figure 3) although, on average (Figure 2), the
benefit is quite strong in this high MELD subgroup.
We computed the rank correlation between the proposed
transplant benefit score and various other scores (Table 5).
The rank correlation (also known as the Spearman corre-
lation) equals the more commonly used correlation coeffi-
cient (also known as the Pearson correlation) computed on
the ranks, rather than the actual scores. The rank correla-
tion is bounded by −1 and 1. A value of 1 (−1) indicates that
as one score increases, the other increases (decreases);
values close to 0 indicate no correspondence between the
two scores. The rank correlation between the proposed
benefit score and MELD score is 0.67, which appears to be
consistent with Figure 3. Although the benefit and MELD
scores are related, it is clear that one score is not dupli-
cating the other, judging by the overlap in benefit scores
among MELD categories. Based on the rank correlation
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Table 5: Rank correlation among scores
Rank
Scores correlation
Transplant benefit score, MELD score 0.67
Predicted 5-year waiting −0.72
list lifetime, MELD score
being only 0.67 and the overlap in Figure 3, it appears that
the ranks of waiting list patients would be altered con-
siderably under a benefit-based allocation system. A rank
correlation of 0.67 is perhaps closer to 1 than expected
since MELD considers waiting list mortality, while the ben-
efit score captures both pre- and posttransplant mortality.
However, the rank correlation between predicted 5-year
waiting list lifetime (the waiting list component of the ben-
efit calculation) and MELD was only −0.72. This is further
away from −1 than one might anticipate given that, in
this case, the rank correlation is being computed on two
quantities intended to measure urgency. The fact that the
rank correlation between our 5-year predicted waiting list
lifetime and MELD is not closer to −1 reflects the fact
that several factors in addition to MELD affect waiting list
mortality.
In Table 6, we further explore the ideas from Table 5. The
rank correlation between predicted 5-year waiting list life-
time and the benefit score was calculated to be −0.89. The
closeness of this particular rank correlation to −1 (which
would indicate that the benefit score could be based on
predicted waiting list lifetime alone) is consistent with the
fact that covariate-adjusted posttransplant death rates are
substantially less than (approximately one fifth) those on
the waiting list (1). As such, there appears to be less vari-
ation in posttransplant outcomes since 5-year survival on
the waiting list is much less than that of posttransplant.
If we restrict attention to patients with positive transplant
benefit scores (those patients much more likely to obtain
offers under a benefit-based allocation system), the rank
correlation between the score and predicted waiting list
lifetime equals −0.90 and hence is approximately equal to
that based on all patients.
To obtain a summary measure of the importance of fac-
tors other than the MELD components, we computed the




Predicted waiting list lifetime All −0.89
Predicted waiting list lifetime Benefit score > 0 −0.90
Benefit score, using MELD All 0.68
components only
Benefit score, using MELD Benefit score > 0 0.61
components only
rank correlation between the proposed benefit score and a
benefit score based on the MELD components alone: 0.68
(Table 6). When restricted to patients with positive (pro-
posed) benefit scores, this correlation decreased to 0.61
(Table 6). In either case, the message is that the MELD
components strongly influence but certainly do not domi-
nate the proposed benefit score.
As a follow-up to Figure 3, in Figure 4 we display box and
whisker plots for benefit scores by age group. Based on
Figure 4, it appears that the proposed benefit score is not
strongly influenced by age, judging by the apparent similar-
ity of the distributions across age groups. This may seem
strange, since age covariates were selected for inclusion in
both the waiting list and posttransplant models. Two things
are important in this regard. First, since age predicts both
pre- and posttransplant survival, it would have a stronger
influence on the benefit score if it predicted one and not
the other, or if it predicted one much more strongly than
the other. Second, although age is predictive of mortality,
it is much less predictive than several factors, such as the
MELD components and albumin.
We sought to rank each patient covariate in the benefit
score in terms of relative importance. To do so, we took
the cross-section of patients active on the waiting list on
May 1, 2004 and computed the benefit score for each pa-
tient using a randomly selected donor from calendar year
2004. We then fitted a linear regression model, with the
benefit score serving as the response variate and each pa-
tient covariate serving as the predictor variates. We judged
the importance of each covariate by the percentage of vari-
ation in the benefit scores it explained. The results of this
exercise are listed in Table 7. Each row can be interpreted
as the contribution of that covariate, after factoring out the
contribution of all covariates listed above. Note that the
ordering was based on a sequence of linear regression
models to determine the most important covariate (which
happened to be albumin), followed by the second most
important covariate (after factoring out the contribution of
albumin), and so on. Albumin accounted for over nearly half
(53%) of the variation in benefit scores. After factoring out
the contribution of albumin, bilirubin accounted for an addi-
tional 15% of the variation. The next most important factor
was donor age (8%). The only remaining covariate, which
accounted for greater than 5% of the variation in the ben-
efit scores, was creatinine (5.3%). Note that recipient age
accounted for less than 5% of the variation in scores. To-
gether, the seven factors listed in Table 7 explained almost
97% of the variation in the benefit scores.
The proposed transplant benefit score is based on a 5-year
timeline, with the truncation point largely chosen based
on data availability. To assess the sensitivity of the patient
rankings to the 5-year truncation time, we computed rank
correlations between the proposed score and those based
on 1-, 3- and 10-year lifetimes (Table 8). Survival models for
the 10-year life expectancies were based on extrapolations,







































Figure 4: Benefit scores by age pa-
tients with benefit > 0.
which assumed that the average hazard during years 5–10
was equal to that during year 4–5. As shown in the top row
of the matrix in Table 8, the 1-year scores have decreasing
rank correlation with the remaining time horizons, with the
correlation decreasing as the time horizon is extended. The
3-, 5- and 10-year scores have pair-wise rank correlations
very close to 1, indicating that the ordering of patients ap-
pears to be quite insensitive to the time horizon, provided
the truncation point is 3 or more years.
Evaluation of Benefit-Based Allocation Via
Simulation
We evaluated the performance of the proposed liver trans-
plant survival benefit score using the Liver Simulated Allo-
cation Model (LSAM) (25). LSAM is part of a family of sim-
ulated allocation models (SAMs) developed by the SRTR.
Similar models exist for kidney/pancreas allocation (KP-
SAM) and the thoracic organs (TSAM). The SAMs have
been used previously many times to assess the future ef-
fect of proposed changes in allocation policy. A schematic
diagram of the general flow of data and event processing
by LSAM is displayed in Figure 5. The model starts with
the actual candidates on the waiting list; in our case, on






Donor age 7.7 78.5
Creatinine 5.3 83.9
Recipient age 4.8 88.6
INR 2.9 91.1
DCD 1.8 93.3
Previous liver transplant 1.8 95.1
Diagnosis 1.7 96.8
Remaining, combined 3.4 100.0
DCD = donation after cardiac death.
INR = international normalized ratio.
January 1, 2006. The model runs for one full calendar year,
processing new wait-listings (i.e. initial listings, relistings),
transplants, deaths and removals from the waiting list for
reasons other than death and transplant. The primary role
of LSAM is to evaluate the changes in experience over
the calendar year due to changes in the allocation system.
Through LSAM, one can assess the impact (e.g. number
of deaths) on 1 year’s worth of experience of changing the
allocation rules, which are programmed directly into LSAM
for each run. Essentially, a waiting list lifetime (i.e. lifetime,
in the absence of transplant) is simulated for each patient.
This lifetime without transplant contains status history
updates, inactive time and, possibly, removal. Deceased-
donor livers arrive into the system and are allocated based
on whatever rules are programmed into a particular LSAM
run. Each organ is offered to patients active on the waiting
list, and each offer is accepted or rejected with a proba-
bility that depends on the patient and donor characteris-
tics. Posttransplant experience is generated for patients
who are transplanted, including death or graft failure and
subsequent relisting. Further details regarding LSAM are
described in Thompson et al. (25).
We evaluated three allocation schemes. The first is the
set of rules currently in place at the time this article is be-
ing written. Note that the SHARE15 rule is incorporated
into the current allocation scheme. The second allocation
system also features MELD/PELD based allocation but is
based on regional sharing for all MELD scores; that is,
local is essentially eliminated as the basis for allocation,
with region then being the first geographic level of offer.
There are two reasons that ‘total’ regional sharing is of
Table 8: Rank correlations between benefit scores using different
truncation points
RANK
Correlation 1 year 3 years 5 years 10 years∗
1 year 1 0.96 0.93 0.91
3 years 1 0.995 0.990
5 years 1 0.997
10 years 1
∗Based on extrapolation.
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Figure 5: Liver Simulated Allocation
Model (LSAM) event processing.
interest. First, it is currently being considered by the OPTN
Liver and Intestine Committee. Second, the SHARE15 rule
has no obvious analog under survival benefit based alloca-
tion, meaning that comparisons between regional sharing
based allocation and the proposed benefit-based system
are easier to interpret than comparisons between the cur-
rent and benefit based system. The third allocation system
evaluated is transplant benefit, again with regional sharing
at all MELD scores.
Results of the LSAM modeling are averaged over 10 itera-
tions. In Table 9, we list the number of deaths, by allocation
system, with the numbers in parentheses representing the
difference between that system and the system in the col-
umn to the immediate left. Based on one calendar year
of experience, benefit based allocation would result in 83
fewer waiting list deaths, six fewer posttransplant deaths
and 13 fewer postremoval deaths, a net saving of 102
lives. Naturally, regional sharing and transplant benefit al-
location systems would result in transplants to different
sets of patients. As such, in Table 10 we estimate the
number of liver transplant-attributable life-years saved un-
der each allocation system. Under a MELD/PELD based
regional sharing system, we estimate that there would be
6273 liver transplants, and that the mean benefit score
would be 1.63 years. Taking the product of these two
numbers, there would be 6273 × 1.63 = 10 225 life-years
saved. Under survival benefit based allocation, there are
projected to be 80 fewer transplants, but the mean ben-
efit score is 0.38 years greater than that under a regional
sharing system. The result is an additional 2223 life-years.
To better appreciate this calculation, recall that a patient’s
Table 9: Liver Simulated Allocation Model (LSAM): number of
deaths by allocation system
Current Regional Transplant
Deaths system sharing benefit
Waiting list 1660 1602 (−58) 1519 (−83)
Posttransplant 609 607 (−2) 601 (−6)
Postremoval 407 397 (−10) 384 (−13)
Total 2675 2606 (−69) 2504 (−102)
benefit score represents their predicted gain in lifetime
(over the next 5 years) due to receiving a transplant. The
total lifetime gained calculation applies the patient/organ-
specific predicted gain in 5-year lifetime to patients who
actually receive a transplant. Naturally, patients who are not
transplanted are predicted to receive no transplant survival
benefit.
Discussion
In this article we describe and evaluate a proposed score
currently being considered to serve as the basis for a trans-
plant survival benefit based deceased-donor liver allocation
system for chronic liver failure patients. The score is cur-
rently being considered by the OPTN Liver and Intestine
Committee and may undergo modification prior to its field
implementation. The proposed score is based on models
of a single end-point, mortality; hence the phrase ‘survival
benefit’. Mortality has always been considered the most
important outcome among organ failure patients. It may
be possible to develop a benefit score that incorporates
morbidity or quality of life measures. It is unclear how such
a score should be constructed, and perhaps most impor-
tantly, it appears that reliable pertinent data are currently
unavailable for outcomes other than death.
This article represents a natural extension of previous work
on liver transplant survival benefit from the SRTR (1,10).
Merion et al. (1) previously demonstrated that the mortal-
ity reduction due to liver transplantation increases with
increasing MELD. Subsequently, Schaubel et al. (10)
Table 10: Liver Simulated Allocation Model (LSAM): life-years
saved by allocation system
Current Regional Transplant
system sharing benefit
Mean benefit score 1.56 1.63 (+0.07) 2.01 (+0.38)
at transplant
Number of transplants 6330 6273 (−27) 6193 (−80)
Life-years saved 9875 10 225 (+350) 12 448 (+2223)
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demonstrated that liver transplant benefit depends not
only on MELD but also on the donor quality, as quanti-
fied by the Donor Risk Index (DRI) (26). Rather than using
only MELD and DRI, the current article proposes a method
for computing liver transplant benefit using all pertinent pa-
tient and donor characteristics. While the work of Merion
et al. (1) and Schaubel et al. (10) compared average pa-
tients, our current proposal focuses on calculations at the
patient level. For example, Merion et al. (1) indicated that,
on average, patients with low MELD do not obtain survival
benefit from liver transplantation. This is consistent with
Figure 3, which indicates that the average benefit score
is negative at low MELD scores. However, Figure 3 also
indicates that there are patients at low MELD scores that
do benefit from a liver transplant; likely not the patients
who receive high DRI livers, judging by our previous work.
We estimate that a substantial number of life-years would
be saved if transplant survival benefit based allocation
were implemented. Comparing a MELD/PELD and ben-
efit based allocations systems with regional sharing, we
estimate that over 2000 life-years would be saved based
on one calendar year’s worth of experience and only con-
sidering the first 5 years posttransplant. It should be noted
that our calculation vastly underestimates the gain in life-
years by the patient population in at least two important
ways. First, only one calendar year of liver transplants was
simulated by LSAM. Second, the benefit score predicts the
gain in lifetime over the next 5 years, as opposed to the
total gain in lifetime.
With respect to model evaluation, the C statistic reflects
the ability of the model to correctly rank patients in terms
of death rate. For the waiting list model C = 0.74, indicating
that among pairs of patients, the model correctly ranked
the death times approximately three times as often as it
did so incorrectly. The corresponding result was less en-
couraging for the posttransplant model, with C = 0.63. It
is possible that the most important determinants of post-
transplant survival are not known at the time of transplant;
for example, events that occur in the post- and periop-
erative period. Additionally, since both patient and donor
factors are important to posttransplant outcomes, unlike
waiting list survival, there are two dimensions upon which
to misclassify liver transplant recipients. For example, al-
though variables like diabetes, mechanical support and pre-
vious abdominal surgery are predefined by the OPTN, the
classifications for such variables are broad and somewhat
subjective. It is thus possible that heterogeneity may ex-
ist across centers with respect to the definitions actually
applied. The posttransplant model is under continued in-
vestigation, with the objective of obtaining a model with
better discriminatory power, using the observed data.
An important concern is how the switch from an alloca-
tion system based on MELD/PELD to a system based on
a benefit score would affect pediatric patients. Under the
MELD/PELD system, patients aged less than 12 years are
given a considerable advantage over adults in terms of pri-
ority. In particular, a patient with PELD x faces considerably
lower waiting list mortality than a patient with a MELD of x.
The advantage given to pediatric patients is implicit, in the
sense that no modification is made to convert the MELD
score into a PELD score for patients age <12 years. In-
stead, MELD and PELD scores are computed using differ-
ent formulas, knowing that MELD more accurately reflects
waiting list mortality risk than PELD. Given that the advan-
tage given to pediatric patients appears to be well accepted
by the liver transplant community, it would presumably be
desirable for the advantage to patients age <12 years to
be preserved under benefit-based allocation. Currently, the
same benefit score is computed for pediatric and adult pa-
tients, with no explicit modification built in to advantage
patients aged <12 years. One possibility is to add a certain
constant (e.g. 0.5 years) to the calculated benefit score for
pediatric patients. A second possibility is to downweight
the role of waiting list life expectancy, which is known to
be quite high among pediatric patients. For example, if the
benefit score is calculated as B = LT–WL for adult patients
(where LT and WL represent posttransplant and waiting
list life expectancy, respectively), then we could set B∗ =
LT – 0.75 × WL for pediatric patients. Preliminary LSAM
results indicate that the percentage of deceased-donor kid-
neys transplanted to pediatric patients would not change
under benefit-based allocation (data not shown). The most
likely reason for the stability across allocation systems,
with respect to the percentage of transplants allocated to
pediatric patients, is the strong impact of donor-to-recipient
size-matching and prioritization to pediatric patients of or-
gans from pediatric donors.
Another important consideration in the transition to
benefit-based allocation is the issue of exception scores.
Currently, patients may apply to their regional review board
to have their allocation MELD score increased. If granted,
such patients will be prioritized based on their ‘exception’
(as opposed to their calculated) MELD score. The intention
is that exception scores be granted in cases where the pa-
tient’s calculated MELD score is known to understate their
true waiting list mortality risk. The benefit score is intended
to explicitly quantify the impact of each patient characteris-
tic that affects the amount of additional lifetime a liver trans-
plant would provide. Therefore, exception scores should
play a greatly reduced role under a benefit-based alloca-
tion system since most factors that, under a MELD/PELD
based system, may have prompted an exception score ap-
plication, would already be accounted for in the benefit
score calculation. That is, patients with a certain condi-
tion would still get a boost in prioritization, provided that
such a boost was consistent with the benefit score, which
is evidence-based. It is possible that exception scores
would still be granted under a benefit based system, for
example, for conditions known to affect waiting list sur-
vival but which are too rare to be reliably incorporated
into the survival models used to build the allocation
score.
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Currently, the most frequently occurring exception is that
for hepatocellular carcinoma (HCC), although exceptions
are granted for many other conditions. As mentioned
previously, HCC is one of the waiting list model covari-
ates. Based on our waiting list model, it is estimated that
HCC patients face a significant 51% increase in covariate-
adjusted waiting list mortality. Since HCC does not signif-
icantly affect posttransplant survival and is therefore not
included in the posttransplant life expectancy computa-
tion, HCC patients would be given an advantage, under
benefit-based allocation, relative to patients without HCC.
This is not to imply that the increased priority offered to
HCC patients would be greater under a benefit- (vs. MELD)
based allocation system. In fact, the opposite may be true,
particularly since the currently applied boost to a MELD
exception score of 22 for HCC patients is likely indefensi-
ble empirically. This issue is currently under investigation,
again using LSAM modeling.
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